Nerandomilast and the Evolving Therapeutic Paradigm in Pulmonary Fibrosis: From Mechanism to Clinical Efficacy
iNew Medicine · 13.04.2026
DOI: 10.1002/inm3.70052 ↗Kurz gefasst
Fachartikel in der Zeitschrift iNew Medicine, online erschienen am 13.04.2026. Verfasst von Qianwen Bai und 4 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
The recent Phase III FIBRONEER trials establish nerandomilast, a novel oral phosphodiesterase 4B (PDE4B) inhibitor, as an effective therapy for idiopathic and progressive pulmonary fibrosis. By elevating cyclic adenosine monophosphate (cAMP), it uniquely dual‐targets the NLRP3 inflammasome and TGF‐β pathway, addressing both inflammation and fibrosis. The trials demonstrated significant slowing of lung function decline, with a manageable safety profile. Critically, its efficacy on background antifibrotic therapy provides robust evidence for viable combination regimens, thereby ushering in a new era of combination therapy for this refractory disease. This marks a paradigm shift, offering renewed hope and paving the way for multi‐targeted treatment strategies, although longer‐term outcomes warrant further study.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Bai, Q., Deng, J., Wang, H., Yao, Y., & Wang, T. (2026). Nerandomilast and the Evolving Therapeutic Paradigm in Pulmonary Fibrosis: From Mechanism to Clinical Efficacy. iNew Medicine. https://doi.org/10.1002/inm3.70052
Vancouver
Bai Q, Deng J, Wang H, Yao Y, Wang T. Nerandomilast and the Evolving Therapeutic Paradigm in Pulmonary Fibrosis: From Mechanism to Clinical Efficacy. iNew Medicine. 2026. doi:10.1002/inm3.70052
BibTeX
@article{Bai2026,
author = {Bai, Qianwen and Deng, Jia and Wang, Hongquan and Yao, Yao and Wang, Tao},
title = {Nerandomilast and the Evolving Therapeutic Paradigm in Pulmonary Fibrosis: From Mechanism to Clinical Efficacy},
journal = {iNew Medicine},
year = {2026},
doi = {10.1002/inm3.70052}
}
EUVIMED